Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives
ReviewHumansOther animals
- Design
- Review
- What was measured
- A review of the possible role of palmitoylethanolamide in metabolic syndrome after menopause
What the authors reported
The authors describe laboratory and preliminary clinical data suggesting effects on blood lipids, insulin sensitivity and inflammation through PPAR-alpha. They state that large clinical studies are needed to establish efficacy, dosing and long-term safety, and that doses in the literature range from 300 to 1,200 mg a day with no clear standard.
Limits of this study
A review that rests mainly on laboratory and early clinical data. It names no completed trial in postmenopausal women. It was funded through an Italian Ministry of Health network, and the authors declared no conflicts.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.